Publications by authors named "Michael Finkler"
Background: 5-aminosalicylates (5-ASA) are used to treat mild to moderate ulcerative colitis. Despite their lack of efficacy in Crohn disease (CD), they are still used in real-world practice. Additionally, when patients have progressive disease, they may escalate to biologic therapy, at which time 5-ASA may or may not be discontinued.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness of therapeutic drug monitoring for pediatric inflammatory bowel disease (IBD) patients using two pharmacokinetic models to analyze adalimumab levels post-induction.
- A retrospective review identified that most patients with Crohn disease required monitoring, and the de Klaver model showed less bias in predicting adalimumab concentrations compared to the Ternant model.
- Findings revealed that nearly 50% of patients needed dose adjustments during maintenance therapy to reach effective drug levels and maintain remission.
Objective: Recent studies have emphasized the early use of infliximab (IFX) in pediatric patients with inflammatory bowel disease. Standard dosing of 5 mg/kg/dose may not be sufficient to achieve optimal clinical outcomes. The aim of our study was to compare short-term outcomes with standard dosing of IFX to higher, nonstandard dosing of IFX for induction therapy.
View Article and Find Full Text PDF